9 completed, 4 recruiting, 2 active not recruiting, 1 terminated. 10 Phase 1, 2 Phase 2, 1 Early Phase 1, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 10 | Completed 7, Recruiting 1, Terminated 1, Withdrawn 1 |
| Phase 2 | 2 | Active not recruiting 1, Recruiting 1 |
| Early Phase 1 | 1 | Recruiting 1 |
| Phase 4 | 1 | Completed 1 |
Follow Malignancies: new trials by email Literature Review of Malignancies trials Research Report on Malignancies
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| JL19001 Injection Alone or in Combination With Standard Therapy in Patients With Advanced Solid Tumors or Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma JL19001, subcutaneous injection, 1 μg/kg, JL19001, subcutaneous injection, 5 μg/kg, JL19001, subcutaneous injection,10 μg/kg - Malignancies, Solid Malignant Tumor | Phase 1 | Recruiting | Jecho Biopharmaceuticals Co., Ltd. | 14 | 2026-06-25 | 2026-08-11 |
| IASO207 Injection in the Treatment of Relapsed/Refractory B-cell Malignancies IASO207 Injection - Malignancies | Early Phase 1 | Recruiting | Peking University People's Hospital | 18 | 2026-05-29 | 2026-06-18 |
| Cancer Therapy-related Cardiac Dysfunction Occuring in Children Treated by Anticancer Drugs for Malignancies use of anticancer drugs in monotherapy or in combination therapy - Malignancies, Cardiovascular Diseases | Unknown | University Hospital, Caen | 10000 | 2024-11-05 | 2024-05-29 | |
| Identifying Tissue-of-origin in Transplant Patients and Patients with Malignancies. Malignancies | Active not recruiting | Hadassah Medical Organization | 1000 | 2024-08-01 | 2024-11-25 | |
| Phase 2, Open-label, Single-arm Study on the Use of Metformin as Adjunctive Therapy in High-grade Glioma Metformin - Glioblastoma, IDH-wildtype, Metformin | Phase 2 | Recruiting | University of Milano Bicocca | 25 | 2024-02-12 | 2025-07-25 |
| A Clinical Study of TAB006 in Patients With Previously Treated, Advanced Malignancies TAB006, Toripalimab - Previously Treated, Advanced, Malignancies | Phase 1 | Withdrawn | Shanghai Junshi Bioscience Co., Ltd. | 2022-03-15 | 2022-05-31 | |
| Outcome of HSCT in Children at Ramathibodi Hospital Hematologic Disease and Disorders, Malignancies | Recruiting | Mahidol University | 200 | 2020-05-08 | 2026-10-05 | |
| 9-ING-41 in Patients With Advanced Cancers 9-ING-41, Gemcitabine - 21 day cycle, Doxorubicin. - Cancer, Pancreatic Cancer | Phase 2 | Active not recruiting | Actuate Therapeutics Inc. | 350 | 2019-01-04 | 2026-04-03 |
| A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies chemotherapy, venetoclax - Malignancies, Acute Lymphoblastic Leukemia (ALL) | Phase 1 | Completed | AbbVie | 143 | 2017-11-08 | 2023-05-22 |
| Study of REGN3767 (Anti-LAG-3) With or Without REGN2810 (Anti-PD1) in Advanced Cancers REGN3767, cemiplimab - Malignancies | Phase 1 | Completed | Regeneron Pharmaceuticals | 333 | 2016-11-07 | 2024-05-01 |
| The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies. Apatinib - Malignancies, Stomach Cancer | Phase 4 | Completed | Shandong Cancer Hospital and Institute | 38 | 2016-09-30 | 2018-02-20 |
| Assessment of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Various Formulations and Doses of PWT-143 PWT-143 - Malignancies | Phase 1 | Completed | MEI Pharma, Inc. | 35 | 2015-06-29 | 2017-08-29 |
| Extended Infusion Carfilzomib on a Weekly Schedule in Patients With Advanced Solid Tumors Carfilzomib, Dexamethasone - Neoplasms, Malignancies | Phase 1 | Completed | Emory University | 22 | 2014-08-01 | 2017-02-07 |
| Longitudinal Evaluation Study of Vaginal Stenosis With and Without Pelvic Radiation Therapy Malignancies, Stenosis of Vagina | Completed | University of Colorado, Denver | 8 | 2013-01-08 | 2017-05-01 | |
| Study of PWT33597 Mesylate in Subjects With Advanced Malignancies PWT33597 mesylate - Malignancies | Phase 1 | Completed | Pathway Therapeutics, Inc. | 22 | 2011-06-01 | 2012-10-25 |
| Study of Satraplatin With Capecitabine to Treat Advanced Solid Malignancies satraplatin and capecitabine - Malignancies | Phase 1 | Terminated | Agennix | 24 | 2006-05-01 | 2012-03-23 |
| Study of L-NDDP (Aroplatin) in Patients With Advanced Solid Malignancies or B-Cell Lymphoma Aroplatin - Malignancies, B-Cell Lymphoma | Phase 1 | Completed | Agenus Inc. | 21 | 2006-03-01 | 2008-10-27 |
| Study of CS-1008 in Patients With Advanced Solid Malignancies and Lymphomas (Without Leukemic Component) CS-1008 (humanized anti-DR5 antibody) - Malignancies, Lymphoma | Phase 1 | Completed | Daiichi Sankyo | 40 | 2007-09-11 |
Neoplasms (18) · Lymphoma, Non-Hodgkin (3) · Breast Neoplasms (2) · Glioma (2) · Recurrence (2) · Bone Neoplasms (1) · Carcinoma, Non-Small-Cell Lung (1) · Cardiovascular Diseases (1) · Colorectal Neoplasms (1) · Disease (1) · Esophageal Neoplasms (1) · Genetic Diseases, Inborn (1) · Glioblastoma (1) · Hematologic Diseases (1) · Hereditary Sensory and Autonomic Neuropathies (1)
Hemic and Lymphatic Diseases (6) · Neoplasms by Histologic Type (6) · Immune System Diseases (5) · Immunoproliferative Disorders (5) · Lymphatic Diseases (5) · Lymphoproliferative Disorders (5) · Lymphoma (4) · Pathologic Processes (4) · Pathological Conditions, Signs and Symptoms (4) · Digestive System Diseases (3) · Digestive System Neoplasms (3) · Neoplasms by Site (3) · Neoplasms, Germ Cell and Embryonal (3) · Neoplasms, Glandular and Epithelial (3) · Neoplasms, Nerve Tissue (3)
3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione (1) · Albumin-Bound Paclitaxel (1) · Calcium Dobesilate (1) · Capecitabine (1) · Carboplatin (1) · Dexamethasone (1) · Doxorubicin (1) · Drug Therapy (1) · Gemcitabine (1) · Injections, Subcutaneous (1) · Irinotecan (1) · Lomustine (1) · Metformin (1) · Paclitaxel (1) · Taxes (1)
AbbVie (1) · Actuate Therapeutics Inc. (1) · Agennix (1) · Agenus Inc. (1) · Daiichi Sankyo (1) · Emory University (1) · Hadassah Medical Organization (1) · Jecho Biopharmaceuticals Co., Ltd. (1) · MEI Pharma, Inc. (1) · Mahidol University (1) · Pathway Therapeutics, Inc. (1) · Peking University People's Hospital (1) · Regeneron Pharmaceuticals (1) · Shandong Cancer Hospital and Institute (1) · Shanghai Junshi Bioscience Co., Ltd. (1)
United States (9) · China (3) · United Kingdom (3) · Australia (2) · Canada (2) · France (2) · Netherlands (2) · Belgium (1) · Germany (1) · Ireland (1) · Israel (1) · Italy (1) · Portugal (1) · South Korea (1) · Spain (1)
Bradley C. Carthon, MD, PhD (1) · Christine Fisher, MD (1) · Joachim Alexandre, MD, PhD (1) · Pui Leung, MBChB (1) · Sheng Yao, PhD (1) · Shuanghu Yuan, MD;PhD (1) · Tamar Hamburger, MRS (1) · Usanarat Anurathapan, MD (1) · William Gradishar, MD (1)
PMID 24327518, PMID 27424289, PMID 28053024, PMID 28672195, PMID 29383130, PMID 29595064, PMID 29846250, PMID 30405781, PMID 30458930, PMID 30975030, PMID 31101621, PMID 31401903, PMID 31533931, PMID 31831767, PMID 31882719, PMID 31894292, PMID 34088831, PMID 35815408, PMID 38900987, PMID 39368878, PMID 39422598, PMID 40062648, PMID 40266036, PMID 41981308
2016 (1), 2017 (1)